Clinical Trials Logo

Ricin Poisoning clinical trials

View clinical trials related to Ricin Poisoning.

Filter by:
  • None
  • Page 1

NCT ID: NCT02386150 Withdrawn - Ricin Poisoning Clinical Trials

ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ — 3-Dose Primary Series With Boost

Start date: October 2017
Phase: Phase 1
Study type: Interventional

This study seeks to determine the safety and immunogenicity of a series of 3 primary vaccinations and a booster vaccination of Recombinant ricin toxin A-chain 1-33/44-198 (rRTA 1-33/44-198) vaccine (RVEc) at 10 or 20 μg intradermally (ID). This study is evaluating if RVEc will display an acceptable safety profile as determined by adverse event (AE) data and if RVEc will elicit anti-ricin antibody titers and ricin toxin-neutralizing antibodies in vaccine recipients.

NCT ID: NCT02385825 Withdrawn - Ricin Poisoning Clinical Trials

IM Recombinant Ricin Toxin Vaccine (RVEc) — 3-Dose Primary Series With Boost

Start date: April 2016
Phase: Phase 1
Study type: Interventional

This study seeks to determine the safety and immunogenicity of a series of 3 primary vaccinations and a booster vaccination of Recombinant ricin toxin A-chain 1-33/44-198 (rRTA 1-33/44-198) vaccine (RVEc) at 10, 50, or 75 μg IM. This study is evaluating if RVEc will display an acceptable safety profile as determined by adverse event (AE) data and if RVEc will elicit anti-ricin antibody titers and ricin toxin-neutralizing antibodies in vaccine recipients.

NCT ID: NCT01846104 Completed - Ricin Poisoning Clinical Trials

Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults

RVEc
Start date: April 30, 2013
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of a single 50-μg booster dose of RVEc. Subjects will be recruited from the cohort that received three 50-μg doses of RVEc in a Phase 1 trial (NCT01317667).